Propanc Biopharma, Inc. vs Prime Medicine, Inc. — Valuation Comparison 2026
Access all valuation models for PPCB vs PRME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →PRME scores higher with a 5.1/10 quality rating vs PPCB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Propanc Biopharma, Inc. (PPCB) and Prime Medicine, Inc. (PRME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
PPCB currently trades at $1.70 with a QOC of 3.7/10, while PRME trades at $3.40 with a QOC of 5.1/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).